Press Releases

Date Title and Summary Additional Formats
Toggle Summary Biocept Issues Letter to Stockholders
SAN DIEGO --(BUSINESS WIRE)--Jan. 12, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular testing to provide physicians with clinically actionable information to improve patient outcomes, announces that President and CEO Michael W.
View HTML
Toggle Summary Biocept to Present at H.C. Wainwright Virtual BioConnect Conference
CEO Michael Nall to participate in diagnostics and devices panel discussion hosted by former FDA Commissioner Dr. Scott Gottlieb SAN DIEGO , Jan. 4, 2021 /PRNewswire/ --  Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to
View HTML
Toggle Summary Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO , Dec. 31, 2020 /PRNewswire/ --   Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, today announced that it has granted
View HTML
Toggle Summary Biocept Enters into Laboratory Services Agreements with Two Southern California Regional Independent Physician Associations
Expands physician and patient access to Biocept's Target Selector™ liquid biopsy testing for the management of patients diagnosed with cancer SAN DIEGO , Dec. 30, 2020 /PRNewswire/ -- Biocept, Inc.  (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services
View HTML
Toggle Summary Biocept Provides Business Update
Announces receipt of more than 150,000 samples for COVID-19 testing and completes relocation to new facility SAN DIEGO , Dec. 14, 2020 /PRNewswire/ --  Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians
View HTML
Toggle Summary Biocept's Target Selector™ Liquid Biopsy Demonstrated High Accuracy When Used for Monitoring the Progression of Metastatic Breast Cancer in Study Conducted at Johns Hopkins Sidney Kimmel Cancer Center
Using Target Selector™ to detect HER2 alterations assists physicians in reassessing therapy options over the course of treating patients with metastatic breast cancer SAN DIEGO , Dec. 10, 2020 /PRNewswire/ --  Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic
View HTML
Toggle Summary Study Shows Biocept's Assays are Viable and Sensitive for Detecting Tumor Cells and Biomarkers in the Cerebrospinal Fluid of Patients with Breast and Lung Cancer that has Metastasized to the Central Nervous System
SAN DIEGO , Nov. 20, 2020 /PRNewswire/ --  Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, announces the results of a study analyzing
View HTML
Toggle Summary Results from Study Using Biocept's Target Selector™ Testing to Monitor Breast Cancer Disease Progression to be Presented at 2020 SABCS®
SAN DIEGO , Nov. 17, 2020 /PRNewswire/ --  Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, announces that results from a prospective
View HTML
Toggle Summary Biocept Reports Third Quarter 2020 Financial Results
Revenues of $6.6 million - a result of decision to offer COVID-19 testing   Conference call begins at 4:30 p.m. Eastern time today SAN DIEGO , Nov. 12, 2020 /PRNewswire/ --  Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to
View HTML
Toggle Summary Biocept Provides Update on COVID-19 Testing with More than 100,000 Samples Received
SAN DIEGO , Nov. 12, 2020 /PRNewswire/ --  Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating patients with cancer, announces an update on its COVID-19 testing with more than 100,000 samples received to date for processing
View HTML